Lv11
8 积分 2024-11-25 加入
Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment
1小时前
待确认
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
3个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
10个月前
已完结
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
10个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
10个月前
已完结
HER2-low breast cancer could be associated with an increased risk of brain metastasis
10个月前
已完结
皖公网安备34019202002308
